Healthcare Industry News: benzoyl peroxide
News Release - June 28, 2006
SkinMedica Appoints Rob Sorensen Vice President, Operations
SAN DIEGO--(HSMN NewsFeed)--June 28, 2006--SkinMedica, Inc. announced today that Rob Sorensen has joined the Company as Vice President, Operations. In this position he will have overall responsibility for all Operations, including contract manufacturing, warehousing and distribution.Most recently, Mr. Sorensen held executive positions with Smith & Nephew and Advanced Tissue Sciences.
"We are fortunate to add someone with Rob's experience to the SkinMedica senior management team" said Rex Bright, President & Chief Executive Officer. "His 25 years of experience will further strengthen our Operations function as we continue our rapid revenue growth and introduction of new products."
Mr. Sorensen is a graduate of the University of the Pacific with a B.S. in Business Administration from the Eberhardt School of Business.
About SkinMedica
SkinMedica is a privately held specialty pharmaceutical company marketing both prescription and cosmeceutical dermatology products. SkinMedica's EpiQuin® Micro (4% Hydroquinone) treats melasma and postinflammatory hyperpigmentation, VANIQA® (eflornithine hydrochloride) Cream, 13.9%, is the only FDA-approved prescription product for the treatment of unwanted facial hair in women, and NeoBenz® Micro, which contains a patented gradual-release formulation of benzoyl peroxide, treats acne. The company's full line of cosmeceutical products, which is sold through physicians, includes TNS Recovery Complex® with NouriCel-MD® to help improve the health and appearance of aging skin. SkinMedica is based in Carlsbad, California. For more information, visit: www.skinmedica.com.
EpiQuin®Micro, NeoBenz® Micro, NouriCel-MD®, SkinMedica®, TNS Recovery Complex® and VANIQA® are trademarks of SkinMedica, Inc.
Source: SkinMedica
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
